Back to Search
Start Over
Treatment of Patients with the Hypereosinophilic Syndrome with Mepolizumab
- Source :
- New England Journal of Medicine. 358:1215-1228
- Publication Year :
- 2008
- Publisher :
- Massachusetts Medical Society, 2008.
-
Abstract
- The primary end point was reached in 84% of patients in the mepolizumab group, as compared with 43% of patients in the placebo group (hazard ratio, 2.90; 95% confidence interval [CI], 1.59 to 5.26; P
- Subjects :
- medicine.medical_specialty
Hypereosinophilic syndrome
business.industry
Hazard ratio
General Medicine
Placebo
medicine.disease
Gastroenterology
Confidence interval
law.invention
Randomized controlled trial
law
Prednisone
Internal medicine
Immunology
medicine
Adverse effect
business
Mepolizumab
medicine.drug
Subjects
Details
- ISSN :
- 15334406 and 00284793
- Volume :
- 358
- Database :
- OpenAIRE
- Journal :
- New England Journal of Medicine
- Accession number :
- edsair.doi.dedup.....115ff08d425c82beffaa08248238cd27